The highlight of the event was a panel discussion on the topic, ‘Is environment consciousness an inhibitor or an inducer…
The highlight of the event was a panel discussion on the topic, ‘Is environment consciousness an inhibitor or an inducer…
The seminar provided in-depth information on DPI technology using properties of lactose powder
Acquires rights to Investigational Anticancer Agent E7777 for US, Europe and certain emerging markets from Eisai
The roundtable explored opportunities in life sciences that India and Scotland can leverage to complement each other
In 2016, the centre will focus a lot on application development and testing, business intelligence and analytics, mobility and support…
The event will be an ideal congregation for companies to pick up on the latest trends and innovations the market…
Awareness was raised on tuberculosis where more than 300 villagers underwent health checkups and were given consultations
The hub will provide pharma and medical device manufacturers with reliable and comprehensive source of information
The company believes that the observations are minor in nature and have been already addressed
Acquires 14 prescription brands Sun Pharma has acquired 14 established prescription brands from Novartis in Japan. According to the agreements…
The product is expected to be launched in Q1 FY16-17
CABAPAN is a cost effective product for the treatment of metastatic castration resistant prostrate cancer
The product is ready to be launched in Q1 FY17
DRL will be granted exclusive US rights for the development and commercialisation of XenoPort’s clinical-stage oral new chemical entity, XP23829…
It is Glenmark’s first injectable approval in the US
Multi-city patient awareness programmes, free diagnosis, rallies, radio, street play and film activity has been planned to raise awareness on…
Warns US pressure on India will continue The Ministry of Commerce recently clarified that media reports claiming that the Government…
The move will help the company to take quick and effective actions to capitalise on opportunities